AKT1 and hepatocellular carcinoma: Importantly, chemical inhibition of Akt kinase with MK2206 or reactivation of PP2A phosphatase activity with specific SMAP represses the tumorigenic effects resulting from the loss of Aldob in vitro and in vivo, further supporting the therapeutic potential of Akt inhibitors or PP2A activators for HCC treatment.